These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 28472558)
1. Cellular glutathione level does not predict ovarian cancer cells' resistance after initial or repeated exposure to cisplatin. Nikounezhad N; Nakhjavani M; Shirazi FH J Exp Ther Oncol; 2017 May; 12(1):1-7. PubMed ID: 28472558 [TBL] [Abstract][Full Text] [Related]
2. Sanguinarine enhances cisplatin sensitivity via glutathione depletion in cisplatin-resistant ovarian cancer (A2780) cells. Sarkhosh-Inanlou R; Molaparast M; Mohammadzadeh A; Shafiei-Irannejad V Chem Biol Drug Des; 2020 Feb; 95(2):215-223. PubMed ID: 31512406 [TBL] [Abstract][Full Text] [Related]
3. Attenuation by glutathione of hsp72 gene expression induced by cadmium in cisplatin-resistant human ovarian cancer cells. Abe T; Gotoh S; Higashi K Biochem Pharmacol; 1999 Jul; 58(1):69-76. PubMed ID: 10403520 [TBL] [Abstract][Full Text] [Related]
4. Reversal of cisplatin resistance in human ovarian cancer cell lines by a c-jun antisense oligodeoxynucleotide (ISIS 10582): evidence for the role of transcription factor overexpression in determining resistant phenotype. Pan B; Yao KS; Monia BP; Dean NM; McKay RA; Hamilton TC; O'Dwyer PJ Biochem Pharmacol; 2002 May; 63(9):1699-707. PubMed ID: 12007573 [TBL] [Abstract][Full Text] [Related]
5. Increased glutathione level is not involved in enhanced bleomycin sensitivity in cisplatin-resistant 2780CP cells. Tanaka T; Kurokawa H; Matsuno K; Matsumoto S; Hayashida Y Anticancer Res; 2008; 28(5A):2663-8. PubMed ID: 19035292 [TBL] [Abstract][Full Text] [Related]
6. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs. Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496 [TBL] [Abstract][Full Text] [Related]
7. Regulation of HtrA2/Omi by X-linked inhibitor of apoptosis protein in chemoresistance in human ovarian cancer cells. Yang X; Xing H; Gao Q; Chen G; Lu Y; Wang S; Ma D Gynecol Oncol; 2005 May; 97(2):413-21. PubMed ID: 15863139 [TBL] [Abstract][Full Text] [Related]
8. Effect of lung resistance-related protein on the resistance to cisplatin in human ovarian cancer cell lines. Wang W; Ke S; Chen G; Gao Q; Wu S; Wang S; Zhou J; Yang X; Lu Y; Ma D Oncol Rep; 2004 Dec; 12(6):1365-70. PubMed ID: 15547764 [TBL] [Abstract][Full Text] [Related]
9. Approach for chemosensitization of cisplatin-resistant ovarian cancer by cucurbitacin B. El-Senduny FF; Badria FA; El-Waseef AM; Chauhan SC; Halaweish F Tumour Biol; 2016 Jan; 37(1):685-98. PubMed ID: 26242260 [TBL] [Abstract][Full Text] [Related]
10. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model. Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121 [TBL] [Abstract][Full Text] [Related]
11. Interference with the expression of β-catenin reverses cisplatin resistance in A2780/DDP cells and inhibits the progression of ovarian cancer in mouse model. Zhao H; Wei W; Sun Y; Gao J; Wang Q; Zheng J DNA Cell Biol; 2015 Jan; 34(1):55-62. PubMed ID: 25211326 [TBL] [Abstract][Full Text] [Related]
12. The role of expression of the components of proteome in the formation of molecular profile of human ovarian carcinoma A2780 cells sensitive and resistant to cisplatin. Chekhun VF; Lukyanova NY; Urchenko OV; Kulik GI Exp Oncol; 2005 Sep; 27(3):191-5. PubMed ID: 16244579 [TBL] [Abstract][Full Text] [Related]
13. Downregulation of vimentin expression increased drug resistance in ovarian cancer cells. Huo Y; Zheng Z; Chen Y; Wang Q; Zhang Z; Deng H Oncotarget; 2016 Jul; 7(29):45876-45888. PubMed ID: 27322682 [TBL] [Abstract][Full Text] [Related]
14. Development of a panel of 15 human ovarian cancer xenografts for drug screening and determination of the role of the glutathione detoxification system. Kolfschoten GM; Pinedo HM; Scheffer PG; Schlüper HM; Erkelens CA; Boven E Gynecol Oncol; 2000 Mar; 76(3):362-8. PubMed ID: 10684711 [TBL] [Abstract][Full Text] [Related]
15. Down-regulation of Ras-related protein Rab 5C-dependent endocytosis and glycolysis in cisplatin-resistant ovarian cancer cell lines. Jin L; Huo Y; Zheng Z; Jiang X; Deng H; Chen Y; Lian Q; Ge R; Deng H Mol Cell Proteomics; 2014 Nov; 13(11):3138-51. PubMed ID: 25096996 [TBL] [Abstract][Full Text] [Related]
16. Higher induction of heat shock protein 72 by heat stress in cisplatin-resistant than in cisplatin-sensitive cancer cells. Abe T; Gotoh S; Higashi K Biochim Biophys Acta; 1999 Apr; 1445(1):123-33. PubMed ID: 10209264 [TBL] [Abstract][Full Text] [Related]
17. Augmentation of transport for cisplatin-glutathione adduct in cisplatin-resistant cancer cells. Goto S; Yoshida K; Morikawa T; Urata Y; Suzuki K; Kondo T Cancer Res; 1995 Oct; 55(19):4297-301. PubMed ID: 7671239 [TBL] [Abstract][Full Text] [Related]
18. NCX-4040, a nitric oxide-releasing aspirin, sensitizes drug-resistant human ovarian xenograft tumors to cisplatin by depletion of cellular thiols. Bratasz A; Selvendiran K; Wasowicz T; Bobko A; Khramtsov VV; Ignarro LJ; Kuppusamy P J Transl Med; 2008 Feb; 6():9. PubMed ID: 18302761 [TBL] [Abstract][Full Text] [Related]
19. Reprogramming of glutamine metabolism via glutamine synthetase silencing induces cisplatin resistance in A2780 ovarian cancer cells. Guo J; Satoh K; Tabata S; Mori M; Tomita M; Soga T BMC Cancer; 2021 Feb; 21(1):174. PubMed ID: 33596851 [TBL] [Abstract][Full Text] [Related]
20. [Relationship between cytochrome c-mediated caspase-3 activity and chemoresistance in cisplatin-resistant human ovarian cancer cell lines]. Yang X; Zheng F; Xing H; Gao Q; Wang W; Lu Y; Wang S; Ma D Zhonghua Zhong Liu Za Zhi; 2002 Nov; 24(6):544-7. PubMed ID: 12667321 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]